BillionToOne, Inc. (BLLN) is a Medical diagnostics research company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for BillionToOne, Inc. in 2026. The next earnings report is expected on September 2, 2026.
BillionToOne, Inc. missed EPS consensus estimates, with EPS of $0.15 falling 18.1% short of the $0.1833 expected, while revenue beat expectations at $109.4 million, exceeding estimates by 0.2%. In the prior quarter both EPS and revenue came in ahead of expectations.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.